

EW/Sec/2024-25/222

October 7, 2024

<b>BSE Limited</b> P J Towers, Dalal Street, Fort, Mumbai – 400 001.  <b>Scrip Code:- 532922</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051.  <b>Symbol:- EDELWEISS</b>
---	---

Dear Sir/Madam,

**Sub: Press Release**

Enclosed is the press release titled “Edelweiss Financial Services Limited announces ₹ 2,000 million Public Issue of Secured Redeemable Non- convertible Debentures (NCDs)” issued by the Company.

Kindly take the same on record.

Thanking you,

Yours faithfully,  
For **Edelweiss Financial Services Limited**

**Tarun Khurana**  
Company Secretary

**Encl.:** as above

## Edelweiss Financial Services Limited announces ₹ 2,000 million Public Issue of Secured Redeemable Non-Convertible Debentures (NCDs)

- Effective Yield of up to 11% per annum\*
- Credit Rating: CRISIL A+/ Watch Negative (placed on 'Rating Watch with Negative Implications') by CRISIL Ratings Limited
- Trading in dematerialized form only
- Allotment, in consultation with BSE Limited (the "**Designated Stock Exchange**"), shall be made on the basis of the date of upload of the application into the electronic book of BSE Limited. However, on the date of oversubscription and thereafter, the allotment shall be made to the applicants on a proportionate basis\*\*\*

**Mumbai, October 7, 2024:** Edelweiss Financial Services Limited ("**EFSL**"/ "**Company**"), today announced the opening of the public issue of Secured Redeemable Non-Convertible Debentures ("**NCDs**") of the face value of ₹ 1,000 each for an amount up to ₹ 1,000 million ("**Base Issue Size**"), with a green shoe option of up to ₹ 1,000 million, cumulatively aggregating up to ₹ 2,000 million ("**Issue Limit**") ("**Issue**").

The Issue has 12 series of NCDs carrying fixed coupons and having a tenure of 24 months, 36 months, 60 months, and 120 months with annual, monthly, and cumulative interest options with an option of staggered redemption in Series IX and XII. Effective annual interest yield on the NCDs ranges from 9.50% p.a. to 11.00% p.a.

The Issue is scheduled to open on October 7, 2024, and close on October 18, 2024\*\*

At least 75% of the funds raised through the Issue will be used for the purpose of repayment/prepayment of interest and principal of existing borrowings of the Company and the balance amount would be utilized for general corporate purposes, subject to such utilization not exceeding 25% of the amount raised in the Issue, in compliance with the Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021, as amended from time to time ("**SEBI NCS Regulations**").

The NCDs proposed to be issued under the Issue have been rated "CRISIL A+/ Watch Negative (placed on 'Rating Watch with Negative Implications') by CRISIL Ratings Limited. Securities with these ratings are considered to have adequate degree of safety regarding timely servicing of financial obligations. Such securities carry low credit risk".

Trust Investment Advisors Private Limited, Nuvama Wealth Management Limited<sup>#</sup> and Tipsons Consultancy Services Private Limited are the Lead Managers to the Issue. The NCDs will be listed on BSE Limited to provide liquidity to the investors.

<sup>#</sup> Nuvama Wealth Management Limited is deemed to be an associate of the Issuer, as per the Securities and Exchange Board of India (Merchant Bankers) Regulations, 1992, as amended (Merchant Bankers Regulations). Further, in compliance with the provisions of Regulation 21A and explanation to Regulation 21A of the Merchant Bankers Regulations, Nuvama Wealth Management Limited would be involved only in marketing of the Issue and as per Regulation 25(3) of the SEBI NCS Regulations and shall not issue a due diligence certificate.

### About Edelweiss Financial Services Limited:

Edelweiss Financial Services Limited ("**EFSL**"), was incorporated on November 21, 1995 under the name of Edelweiss Capital Limited and started operations as an investment banking firm after receipt of a Category II license from SEBI. Edelweiss Capital Limited subsequently received a Category I Merchant Banker license from SEBI with effect from October 16, 2000. The name of Edelweiss Capital Limited was changed to 'Edelweiss Financial Services Limited' with effect from August 1, 2011.

The equity shares of EFSL were listed in December 2007 on BSE Limited and National Stock Exchange of India Limited under the symbols NSE: EDELWEISS, BSE: 532922, Reuters: EDEL.NS and EDEL.BO and Bloomberg: EDEL IS and EDEL IB. The Corporate Identity Number of EFSL is L99999MH1995PLC094641.

After commencing the business as an investment banking firm, the Issuer, through its subsidiaries has diversified its businesses to retail and corporate credit, mutual fund, alternative asset management, asset reconstruction, life insurance and general insurance businesses. We believe that our focus on product innovation and a seamless customer experience has helped expand our retail footprint to approximately ~8.2 million customers. Its research driven approach and consistent ability to capitalize on emerging market trends has further enabled it to foster strong relationships across client segments including corporates, institutions (both domestic and international), high networth individuals and retail clients with a pan-India and international network with 251 (two hundred and fifty one) domestic offices, and 3 (three)

international offices (total 254 offices) and employed 5,889 employees as at June 30, 2024.

**DISCLAIMER**

\*For further details refer to section titled “Issue Related Information” on page 261 of the Prospectus dated September 30, 2024.

\*\*\*Allotment in the public issue of debt securities should be made on the basis of date of upload of each application into the electronic book of the stock exchange. However, on the date of oversubscription and thereafter, the allotments should be made to the applicants on proportionate basis.

\*\* The Issue shall remain open for subscription on Working Days from 10 a.m. to 5 p.m. (Indian Standard Time) during the period indicated in the Prospectus, except that the Issue may close on such earlier date or extended date (subject to a minimum period of 2 (two) working days and a maximum period of 10 (ten) working days from the date of opening of the Issue) as may be decided by the Board of Directors of the Issuer or the Debenture Fund Raising Committee, thereof, subject to relevant approvals. In the event of an early closure or extension of the Issue; the Issuer shall ensure that notice of the same is provided to the prospective investors through an advertisement in a daily national newspaper with wide circulation and a regional daily at the place where the registered office of the Issuer is situated on or before such earlier or extended date of Issue closure. Applications Forms for the Issue will be accepted only from 10:00 a.m. to 5:00 p.m. or such extended time as may be permitted by BSE, on Working Days during the Issue Period. On the Issue Closing Date, Application Forms will be accepted only between 10:00 a.m. to 3:00 p.m. and uploaded until 5:00 p.m. (Indian Standard Time) or such extended time as may be permitted by BSE. Further, pending mandate requests for bids placed on the last day of bidding will be validated by 5 PM on one Working Day after the Issue Closing Date. For further details please refer to the chapter titled “Issue Related Information” on page 261 of the Prospectus.

**DISCLAIMER**

Edelweiss Financial Services Limited (“Company”), subject to market conditions, and other considerations, is proposing a public issue of secured redeemable non-convertible debentures (“NCDs”) and has filed a prospectus dated September 30, 2024 (“Prospectus”) with the Registrar of Companies, Maharashtra at Mumbai (“RoC”), BSE Limited (“BSE”) and Securities and Exchange Board of India (“SEBI”). The Prospectus is available on the website of the Company at [www.edelweissfin.com](http://www.edelweissfin.com), on the website of BSE at [www.bseindia.com](http://www.bseindia.com), on the website of the lead managers at <https://www.trustgroup.in/>, [www.tipsons.com](http://www.tipsons.com) and [www.nuvama.com](http://www.nuvama.com) and on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in). Investors proposing to participate in the Issue should invest only on the basis of the information contained in the Prospectus. Investors should note that investment in the NCDs involves a high degree of risk and for details in relation to the same, refer to the Prospectus, including the section titled “Risk Factors” and “Material Developments” beginning on page 18 and 190 respectively of the Prospectus.

Capitalised terms not defined herein shall have the same meaning as assigned to such terms in the Prospectus.

**DISCLAIMER:** Investors proposing to participate in the Issue should note that investment in the NCDs involves a high degree of risk and for details in relation to the same, refer to the Prospectus dated September 30, 2024, including the sections titled “Risk Factors” and “Material Developments” beginning on pages 18 and 190 respectively of the Prospectus. The Issuer and the Lead Managers accept no responsibility for statements made otherwise than in the Prospectus or in the advertisement or any other material issued by or at the instance of the Company and that anyone placing reliance on any other source of information would be doing so at their own risk.

**DISCLAIMER CLAUSE OF BSE:** It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the Draft Offer Document has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the Prospectus. The investors are advised to refer to the Draft Offer Document/ Offer Document for the full text of the disclaimer clause of the BSE.

**DISCLAIMER CLAUSE OF USE OF BSE ELECTRONIC PLATFORM:** It is to be distinctly understood that the permission given by the BSE to use their network and software of the Online system should not in any way be deemed or construed as compliance with various statutory requirements approved by the Exchange; not does it in any manner warrant, certify or endorse the correctness or completeness of any of the compliance with the statutory and other requirements; nor does it take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company.

**DISCLAIMER STATEMENT OF CRISIL**

CRISIL Ratings Limited (“CRISIL Ratings”) has taken due care and caution in preparing the Material based on the information provided by its client and / or obtained by CRISIL Ratings from sources which it considers reliable (Information). A rating by CRISIL Ratings reflects its current opinion on the likelihood of timely payment of the obligations under the rated instrument and does not constitute an audit of the rated entity by CRISIL Ratings. CRISIL Ratings does not guarantee the completeness or accuracy of the information on which the

rating is based. A rating by CRISIL Ratings is not a recommendation to buy, sell, or hold the rated instrument; it does not comment on the market price or suitability for a particular investor. The Rating is not a recommendation to invest / disinvest in any entity covered in the Material and no part of the Material should be construed as an expert advice or investment advice or any form of investment banking within the meaning of any law or regulation. CRISIL Ratings especially states that it has no liability whatsoever to the subscribers / users / transmitters/ distributors of the Material. Without limiting the generality of the foregoing, nothing in the Material is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary permission and/or registration to carry out its business activities in this regard. Edelweiss Financial Services Limited will be responsible for ensuring compliances and consequences of non-compliances for use of the Material or part thereof outside India. Current rating status and CRISIL Ratings's rating criteria are available without charge to the public on the website, CRISIL Ratings. For the latest rating information on any instrument of any company rated by CRISIL Ratings, please contact Customer Service Helpdesk at CRISIL Ratings.

#### DISCLAIMER CLAUSE OF CARE ANALYTICS & ADVISORY PRIVATE LIMITED

The report is prepared by CARE Analytics and Advisory Private Limited (CareEdge Research). CareEdge Research has taken utmost care to ensure accuracy and objectivity while developing the report based on information available in CareEdge Research's proprietary database, and other sources considered by CareEdge Research as accurate and reliable including the information in public domain. The views and opinions expressed herein do not constitute the opinion of CareEdge Research to buy or invest in this industry, sector or companies operating in this sector or industry and is also not a recommendation to enter into any transaction in this industry or sector in any manner whatsoever.

The report has to be seen in its entirety; the selective review of portions of the report may lead to inaccurate assessments. All forecasts in the report are based on assumptions considered to be reasonable by CareEdge Research; however, the actual outcome may be materially affected by changes in the industry and economic circumstances, which could be different from the projections.

Nothing contained in the report is capable or intended to create any legally binding obligations on the sender or CareEdge Research which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. CareEdge Research is also not responsible for any errors in transmission and specifically states that it, or its directors, employees, parent company – care ratings ltd., or its directors, employees do not have any financial liabilities whatsoever to the subscribers/users of the report. The subscriber/user assumes the entire risk of any use made of the report or data herein. The report is for the information of the authorised recipient in India only and any reproduction of the report or part of it would require explicit written prior approval of CareEdge Research.

CareEdge Research shall reveal the report to the extent necessary and called for by appropriate regulatory agencies, viz., SEBI, RBI, Government authorities, etc., if it is required to do so. By accepting a copy of the Report, the recipient accepts the terms of this Disclaimer, which forms an integral part of the Report.

***For Further details please contact:***

**Edelweiss**

[mediaqueries@edelweissfin.com](mailto:mediaqueries@edelweissfin.com)

**Concept PR**

Archana Parthasarathy

+91 9920940003

[archana@conceptpr.com](mailto:archana@conceptpr.com)